Objective To explore the effects of peridopril on vascular inflammation and vascular endothelium function in mild to moderate essential hypertensive (EH) patients.
Methods 140 EH patients were divided into peridopril group (70 cases) and conventional treatment group (70 cases). 70 cases of healthy volunteers were selected as a control group. We examined the blood express levels of high sensitivity C-reactive protein(hs-CRP), IL-6, ICAM-1, Fibrinogen C(FIB-C)and endothelium 1 (ET-1), nitric oxide (NO) levels and flow mediated dilatation (FMD) in brachial artery blood samples as well as angiotension before beginning treatment in each group, The peridopril group received a 4 mg tablet daily for 4 weeks. in addition to similar drug therapies as those in the conventional treatment group.
Results All EH patients' blood levels of hs-CRP, IL-6, ICAM-1, FIB-C and ET-1 increased significantly (all p < 0.01), while NO and FMD decreased significantly compared with control group (all p < 0.01). In the peridopril group after 4 weeks treatment, the serum levels of hs-CRP, IL-6, ICAM-1, FIB-C and ET-1 as well as angiotension II decreased significantly (all p < 0.01), the level of NO and FMD increased significantly (p < 0.01, p < 0.05) compared with pre-treatment, The levels of angiotensionII decreased significantly (p < 0.05), compared with pre-treatment in the conventional treatment group, while those other index above appeared to have no significant change compared with pre-treatment in the conventional treatment group.
Conclusions Peridopril tablet can inhibit vascular inflammation and protect the vascular endothelium function of EH patients. It is likely this plays an important role in the prevention of thrombotic diseases induced by hypertension.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.